tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Provention Bio (PRVB), Bausch Health Companies (BHC) and Sangamo Biosciences (SGMO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Provention Bio (PRVBResearch Report), Bausch Health Companies (BHCResearch Report) and Sangamo Biosciences (SGMOResearch Report).

Provention Bio (PRVB)

RBC Capital analyst Gregory Renza maintained a Hold rating on Provention Bio on February 24 and set a price target of $8.00. The company’s shares closed last Friday at $6.52.

According to TipRanks.com, Renza is a 1-star analyst with an average return of -3.2% and a 36.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Pacira Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Provention Bio with a $16.33 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Bausch Health Companies (BHC)

In a report issued on February 24, Douglas Miehm from RBC Capital maintained a Buy rating on Bausch Health Companies, with a price target of C$32.00. The company’s shares closed last Friday at $24.35.

According to TipRanks.com, Miehm is ranked #4443 out of 7800 analysts.

Bausch Health Companies has an analyst consensus of Moderate Buy, with a price target consensus of $26.06.

Sangamo Biosciences (SGMO)

In a report issued on February 24, Luca Issi from RBC Capital maintained a Buy rating on Sangamo Biosciences, with a price target of $22.00. The company’s shares closed last Friday at $5.90, close to its 52-week low of $5.13.

According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -27.4% and a 21.6% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crispr Therapeutics AG, and Ionis Pharmaceuticals.

Sangamo Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $14.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PRVB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More